ArticleOncoimmunology2023

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition.

Tom van den Ende et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.